Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02355210 · ClinicalTrials.gov registry record · NA
Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults
A NA study of Intestinal Microbiota and Barrier Function, sponsored by Rush University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 151
- Enrollment target
- 1
- Study location
NCT02355210: Completed NA study of Intestinal Microbiota and Barrier Function, sponsored by Rush University Medical Center.
NCT02355210 is a NA study of Intestinal Microbiota and Barrier Function that has completed, run by Rush University Medical Center. The registered enrollment target is 151 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02355210, a NA study of Intestinal Microbiota and Barrier Function, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 151 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the effect of a dietary supplement to improve gut health. The participants will take one of six dietary treatments for three weeks, and the gut bacteria and the gut intestinal barrier will be assessed to determine if these dietary treatments beneficially change these markers of gut health.
Primary Outcome
change in microbiota composition, including presence of B. adolescentis BD1 and B. animalis supsp lactis BB-12
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Bifidobacteria adolescentis BD1
- DIETARY_SUPPLEMENT Bifidobacteria animalis subsp. lactis BB-12
- DIETARY_SUPPLEMENT Bifidobacteria adolescentis BD1 and galactooligosaccharide
- DIETARY_SUPPLEMENT Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide
- DIETARY_SUPPLEMENT galactooligosaccharide
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-10 |
| Phase | NA |
What the finished NCT02355210 record still lists
NCT02355210 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Intestinal Microbiota and Barrier Function appearing as the primary indexed condition, and to 5 interventions - of which Bifidobacteria adolescentis BD1 is the first listed.
NCT02355210 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02355210 about?
NCT02355210 is a clinical study titled "Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults". This study evaluates the effect of a dietary supplement to improve gut health. The participants will take one of six dietary treatments for three weeks, and the gut bacteria and the gut intestinal barrier will be assessed to determine if these dietary treatments beneficially change these markers of ...
What is the current status of trial NCT02355210?
This trial is currently completed. It is a NA study. The enrollment target is 151 participants. The study started on 2013-06. Estimated completion is 2015-10.
What conditions does trial NCT02355210 study?
This clinical trial studies the following conditions: Intestinal Microbiota and Barrier Function.
What interventions are being tested in trial NCT02355210?
The interventions under investigation include: Bifidobacteria adolescentis BD1 (DIETARY_SUPPLEMENT), Bifidobacteria animalis subsp. lactis BB-12 (DIETARY_SUPPLEMENT), Bifidobacteria adolescentis BD1 and galactooligosaccharide (DIETARY_SUPPLEMENT), Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide (DIETARY_SUPPLEMENT), galactooligosaccharide (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02355210?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02355210 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02355210's enrollment target sits among peer trials
151 661st of 2000 higher than 1,340 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia